

## Human S100P Low Endotoxin Low Endotoxin & Sterilized

Cat# CY-R2467

Amount: 100 µg (2.0 µg/µl)

Lot:

### Introduction:

Members of the S100 family are low molecular mass acidic proteins characterized by cell-type-specific expression and the presence of EF-hand Ca<sup>2+</sup>-binding domains. One of the least studied members of the S100 family is S100P, a 95-amino acid protein first purified from placenta with a restricted cellular distribution. The molecular structure of S100P has been well described and supports its classification in the S100 family of proteins. Expression of S100P has been noted in esophageal epithelial cells during their differentiation, indicating that it may play a role in normal development. There is also considerable evidence that S100P plays a role in cancer. S100P expression has been noted in various cancer cell lines including breast cancer, where it was associated with cellular immortalization, and colon cancer, where its expression was elevated in doxorubicin-resistant cells. S100P has also been shown to be expressed in tumors, including prostate cancer, where its expression is androgen-sensitive, and pancreatic adenocarcinoma, where expression has been localized to the neoplastic epithelium of pancreatic. Furthermore, S100P expression has been shown to be correlated with decreased survival in patients with lung cancer.

### Product Description:

Full length of human S100P, containing an N-terminal GST tag, expressed in *E. coli*.

### Gene Information:

The gene accession number is NM\_005980.

### Gene Aliases:

### Formulation:

Supplied frozen in 2X phosphate buffered saline (2X PBS) containing 50 % glycerol.

### Endotoxin Concentration:

< 0.01 EU/µg as determined by Limulus Amebocyte Lysate (LAL) assay

**Molecular Weight:**

Mw  
97 kDa —  
66 kDa —  
45 kDa —  
31 kDa —  
21.5 kDa —

The recombinant human S100P demonstrates approximately 34 kDa band by SDS-PAGE analysis.

**Storage:**

Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, AVOID REPEATED HANDLING AND MULTIPLE FREEZE/THAW CYCLES.

**Stability:**

Unopened vial at -70 °C, for 1 year after delivery.

**References:**

1. Becker, T., Gerke, V., Kube, E., and Weber, K. (1992) Eur. J. Biochem. 207, 541–547
2. Emoto, Y., et al. (1992) Biochem. Biophys. Res. Commun. 182, 1246–1253
3. Zhang, H., et al. (2003) J. Mol. Biol. 325, 785–794
4. Sato, N., and Hitomi, J. (2002) Anat. Rec. 267, 60–69
5. Guerreiro, D. S. et al. (2000) Int. J. Oncol. 16, 231–240
6. Bertram, J. et al. (1998) Anticancer Drugs 9, 311–317
7. Averboukh, L. et al. (1996) Prostate 29, 350–355
8. Logsdon, C. D. et al. (2003) Cancer Res. 63, 2649–2657
9. Beer, D. G. et al. (2002) Nat. Med. 8, 816–824

**Related Products**

- \* CircuLex S100A13 ELISA Kit: Cat# CY-8057
- \* CircuLex S100A12 ELISA Kit: Cat# CY-8058
- \* CircuLex S100P ELISA Kit: Cat# CY-8060
- \* CircuLex S100A8-MRP8 ELISA Kit: Cat# CY-8061
- \* CircuLex S100A9-MRP14 ELISA Kit: Cat# CY-8062
- \* CircuLex S100A11 ELISA Kit: Cat# CY-8063
- \* CircuLex S100A14 ELISA Kit: Cat# CY-8064
- \* CircuLex S100A7/Psoriasin ELISA Kit: Cat# CY-8073
- \* CircuLex S100A4 ELISA Kit Ver.2: Cat# CY-8086
  
- \* Anti-Human S100A3 (Clone YK-3E3): Cat# CY-M1039
- \* Anti-Human S100A4 (p9Ka): Cat# CY-P1026
- \* Anti-Human S100P: Cat# CY-P1028
- \* Anti-Human S100A10: Cat# CY-P1033



Human S100P Low Endotoxin  
Product Data Sheet

For Research Use Only, Not for use in diagnostic procedures

- \* Anti-Human S100A16: Cat# CY-P1034
- \* Anti-Human S100A3: Cat# CY-P1039
- \* Anti-Human S100A2: Cat# CY-P1040
  
- \* Human S100B: Cat# CY-R2250
- \* Human S100A1: Cat# CY-R2251
- \* Human S100A2: Cat# CY-R2252
- \* Human S100A3: Cat# CY-R2253
- \* Human S100A4: Cat# CY-R2254
- \* Human S100A5: Cat# CY-R2255
- \* Human S100A6: Cat# CY-R2256
- \* Human S100A7: Cat# CY-R2257
- \* Human S100A8: Cat# CY-R2258
- \* Human S100A9: Cat# CY-R2259-G
- \* Human S100A9: Cat# CY-R2259-H
- \* Human S100A10: Cat# CY-R2260
- \* Human S100A12: Cat# CY-R2262-G
- \* Human S100A12: Cat# CY-R2262-H
- \* Human S100A13: Cat# CY-R2263
- \* Human S100A14: Cat# CY-R2264
- \* Human S100A16: Cat# CY-R2266
- \* Human S100P: Cat# CY-R2267
- \* Human S100A11: Cat# CY-R2269
  
- \* Human S100A1 Low Endotoxin: Cat# CY-R2451
- \* Human S100A3 Low Endotoxin: Cat# CY-R2453
- \* Human S100A4 Low Endotoxin: Cat# CY-R2454
- \* Human S100A7 Low Endotoxin: Cat# CY-R2457
- \* Human S100A8 Low Endotoxin: Cat# CY-R2458
- \* Human S100A9 Low Endotoxin: Cat# CY-R2459-G
- \* Human S100A11 Low Endotoxin: Cat# CY-R2461
- \* Human S100A12 Low Endotoxin: Cat# CY-R2462-G
- \* Human S100A14 Low Endotoxin: Cat# CY-R2464
- \* Human S100P Low Endotoxin: Cat# CY-R2467

**PRODUCED BY**

CycLex Co., Ltd.  
1063-103 Terasawaoka  
Ina, Nagano 396-0002  
Japan  
Fax: +81-265-76-7618  
e-mail: [info@cyclex.co.jp](mailto:info@cyclex.co.jp)  
URL: <http://www.cyclex.co.jp>

CycLex/CircuLex products are supplied for research use only. CycLex/CircuLex products and components thereof may not be resold, modified for resale, or used to manufacture commercial products without prior written approval from CycLex Co., Ltd.. To inquire about licensing for such commercial use, please contact us via email.